苑東生物(688513.SH):擬受讓參股公司上海超陽部分股權
格隆匯6月26日丨苑東生物(688513.SH)公佈,爲更好地實施公司戰略發展規劃,加快推進公司創新轉型戰略的實施步伐,公司於2025年6月26日召開第四屆董事會第五次會議審議通過《關於受讓參股公司部分股權暨關聯交易的議案》,同意由公司全資子公司上海投資公司作爲投資主體受讓上海超陽原股東吳漢超、齊力佳持有的部分股權,其中,擬以810萬元人民幣受讓吳漢超所持有的上海超陽7.9545%的股權,對應上海超陽註冊資本700萬元;擬以1,158萬元人民幣受讓齊力佳所持有的上海超陽11.3636%的股權,對應上海超陽註冊資本1,000萬元;資金來源均爲自有資金。
本次交易完成後,公司間接持有上海超陽的股權比例將由11.3636%增加至30.6818%,上海超陽將成爲公司施加重大影響的參股公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.